Studies of Therapeutic Strategies for Atrial Fibrillation Based on a Biophysical Model of the Human Atria

2010 ◽  
pp. 63-79 ◽  
Author(s):  
Laurent Uldry ◽  
Nathalie Virag ◽  
Jean-Marc Vesin ◽  
Lukas Kappenberger
Keyword(s):  
Atrial Fibrillation ◽  
Therapeutic Strategies ◽  
Biophysical Model

scholarly journals Daily Supplementation of L-Glutamine in Atrial Fibrillation Patients: The Effect on Heat Shock Proteins and Metabolites

Cells ◽  
2020 ◽  
Vol 9 (7) ◽  
pp. 1729 ◽  
Author(s):  
Roeliene Starreveld ◽  
Kennedy S. Ramos ◽  
Agnes J. Q. M. Muskens ◽  
Bianca J. J. M. Brundel ◽  
Natasja M. S. de Groot
Keyword(s):  
Atrial Fibrillation ◽  
Heat Shock ◽  
Metabolic Pathways ◽  
Serum Levels ◽  
Therapeutic Strategies ◽  
Glutamine Supplementation ◽  
Novel Therapies ◽  
Cardioprotective Effects ◽  
Baseline Levels ◽  
Shock Proteins

Pharmaco-therapeutic strategies of atrial fibrillation (AF) are moderately effective and do not prevent AF onset and progression. Therefore, there is an urgent need to develop novel therapies. Previous studies revealed heat shock protein (HSP)-inducing compounds to mitigate AF onset and progression. Such an HSP inducing compound is L-glutamine. In the current study we investigate the effect of L-glutamine supplementation on serum HSP27 and HSP70 levels and metabolite levels in patients with AF patients (n = 21). Hereto, HSP27 and HSP70 levels were determined by ELISAs and metabolites with LC-mass spectrometry. HSP27 levels significantly decreased after 3-months of L-glutamine supplementation [540.39 (250.97–1315.63) to 380.69 (185.68–915.03), p = 0.004] and normalized to baseline levels after 6-months of L-glutamine supplementation [634.96 (139.57–3103.61), p < 0.001]. For HSP70, levels decreased after 3-months of L-glutamine supplementation [548.86 (31.50–1564.51) to 353.65 (110.58–752.50), p = 0.045] and remained low after 6-months of L-glutamine supplementation [309.30 (118.29–1744.19), p = 0.517]. Patients with high HSP27 levels at baseline showed normalization of several metabolites related to the carbohydrates, nucleotides, amino acids, vitamins and cofactors metabolic pathways after 3-months L-glutamine supplementation. In conclusion, L-glutamine supplementation reduces the serum levels of HSP27 and HSP70 within 3-months and normalizes metabolite levels. This knowledge may fuel future clinical studies on L-glutamine to improve cardioprotective effects that may attenuate AF episodes.

scholarly journals A biophysical model of atrial fibrillation to define the appropriate ablation pattern in modified maze

2007 ◽  
Vol 31 (1) ◽  
pp. 65-69 ◽  
Author(s):  
Patrick Ruchat ◽  
Lam Dang ◽  
Nathalie Virag ◽  
Jürg Schlaepfer ◽  
Ludwig Karl von Segesser ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Biophysical Model ◽  
Ablation Pattern

scholarly journals Atrial septal pacing for the termination of atrial fibrillation: study in a biophysical model of human atria

EP Europace ◽  
2012 ◽  
Vol 14 (suppl 5) ◽  
pp. v112-v120 ◽  
Author(s):  
L. Uldry ◽  
N. Virag ◽  
F. Lindemans ◽  
J.-M. Vesin ◽  
L. Kappenberger
Keyword(s):  
Atrial Fibrillation ◽  
Biophysical Model ◽  
Septal Pacing

scholarly journals Therapeutic Strategies for Atrial Fibrillation

2007 ◽  
Vol 96 (5) ◽  
pp. 1014-1019
Author(s):  
Gaku Sekita ◽  
Hiroyuki Daida
Keyword(s):  
Atrial Fibrillation ◽  
Therapeutic Strategies

scholarly journals Atrial slow conduction develops and dynamically expands during premature stimulation in an animal model of persistent atrial fibrillation

PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0258285
Author(s):  
Matthias Lange ◽  
Annie M. Hirahara ◽  
Ravi Ranjan ◽  
Gregory J. Stoddard ◽  
Derek J. Dosdall
Keyword(s):  
Atrial Fibrillation ◽  
Conduction Velocity ◽  
Conduction Block ◽  
Persistent Atrial Fibrillation ◽  
Therapeutic Strategies ◽  
Propagation Direction ◽  
Slow Conduction ◽  
Cycle Lengths ◽  
Image Position ◽  
Activation Times

Slow conduction areas and conduction block in the atria are considered pro-arrhythmic conditions. Studies examining the size and distribution of slow conduction regions in the context of persistent atrial fibrillation (AF) may help to develop improved therapeutic strategies for patients with AF. In this work, we studied the differences of size and number in slow conduction areas between control and persistent AF goats and the influence of propagation direction on the development of these pathological conduction areas. Epicardial atrial electrical activations from the left atrial roof were optically mapped with physiological pacing cycle lengths and for the shortest captured cycle lengths. The recordings were converted to local activation times and conduction velocity measures. Regions with slow conduction velocity (less than 0 . 2 m s) were identified. The size of the connected regions and the number of non-connected regions were counted for propagation from different orthogonal directions. We found that regions of slow conduction significantly increases in our 15 persistent AF goat recordings in response to premature stimulation (24.4±4.3% increase to 36.6±4.4%, p < 0.001). This increase is driven by an increase of size from (3.70±0.89[mm2] to 6.36±0.91[mm2], p = 0.014) for already existing regions and not by generation of new slow conduction regions (11.6±1.8 vs. 13±1.9, p = 0.242). In 12 control goat recordings, no increase from baseline pacing to premature pacing was found. Similarly, size of the slow conduction areas and the count did not change significantly in control animals.

scholarly journals Use of a biophysical model of atrial fibrillation in the interpretation of the outcome of surgical ablation procedures☆

2007 ◽  
Vol 32 (1) ◽  
pp. 90-95 ◽  
Author(s):  
Patrick Ruchat ◽  
Lam Dang ◽  
Jürg Schlaepfer ◽  
Nathalie Virag ◽  
Ludwig Karl von Segesser ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Biophysical Model ◽  
Surgical Ablation

scholarly journals The patient with atrial fibrillation undergoing percutaneous angioplasty: triple therapy or new therapeutic strategies?

ABOUTOPEN ◽  
2018 ◽  
Vol 4 (1) ◽  
pp. 116-121
Author(s):  
Gianluca Campo ◽  
Giulia Bugani
Keyword(s):  
Atrial Fibrillation ◽  
Triple Therapy ◽  
Antithrombotic Therapy ◽  
Scientific Evidence ◽  
Oral Anticoagulants ◽  
Dual Therapy ◽  
Clinical History ◽  
Bleeding Risk ◽  
Therapeutic Strategies ◽  
Thrombotic Risk

The management of antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) is a challenge cardiologists face daily. The main difficulty is represented by finding the right balance between the prevention of thrombotic risk and the inevitable increase in bleeding. Most guidelines recommend the use of both oral anticoagulants and dual antiplatelet therapy in combination (triple therapy) in patients with FA undergoing PCI, suggesting however immediate use of dual antithrombotic therapy in patients with prevalent bleeding risk. Many studies show that triple therapy is associated with high frequency of major bleeding, thus stimulating the research for new therapeutic strategies. We report the case of a patient suffering from hypertension, dyslipidemia and epistaxis, hospitalized for the onset of angina associated with moderate efforts. Despite scientific evidence to support the use of dual therapy with dabigatran, the patient's detailed clinical history shows that this type of approach has not yet entered into current clinical practice, although the final therapeutic choice is in line with the results of the RE-DUAL PC study (Cardiology).

Sign in / Sign up

Export Citation Format

Share Document